Equities

BibbInstruments AB

BibbInstruments AB

Actions
  • Price (SEK)4.26
  • Today's Change-0.14 / -3.18%
  • Shares traded45.87k
  • 1 Year change+12.70%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BibbInstruments AB is a Sweden-based medical technology company. It develops and sales biopsy instruments, which are based on technology platform EndoDrill. The drill function enables early cancer diagnosis, especially in deep skin tissues. The portfolio includes EndoDrill GI Upper for stomach biopsy, EndoDrill GI Lower for intestinal biopsy, EndoDrill GI Lung for lung biopsy, EndoDrill Therapy to pass displacements in different organs for placement of conductors, balloons and stents for treatment, EndoDrill Needle for breasts biopsy, as well as EndoDrill Model X for multiple areas and falls under independent research project. Products are distributed to hospitals with endoscopy specialists’ centers and surgical wards. The Company’s primary distribution focus is Scandinavian countries.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-11.84m
  • Incorporated2013
  • Employees4.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Codelab Capital AS-97.07bn-97.07bn83.30m29.00--0.5169----------0.4624-----------6.63---7.43--83.80---39.82----0.00---69.66-3.83119.43---12.19--
Kontigo Care AB29.65m1.75m83.32m10.0037.471.7215.712.810.06940.06941.111.510.6241--8.03--3.68-0.42145.03-0.619569.9366.315.89-0.5205--10.000.0569--1.8016.95-92.68--44.94--
SciBase Holding AB (publ)25.71m-59.24m86.50m27.00--1.64--3.36-0.4495-0.44950.18840.24090.2990.73284.04952,222.30-68.89-68.63-89.67-87.7770.0261.28-230.41-300.203.11-62.080.00--29.9327.50-28.75--5.15--
Toleranzia AB0.00-5.41m92.62m11.00--0.6129-----0.026-0.0260.000.76680.00----0.00-3.89-7.45-4.05-7.78------------0.00------11.79--63.90--
Clinical Laserthermia Systems AB15.20m-68.04m93.47m7.00--1.02--6.15-10.14-10.142.195.320.28711.204.24---130.42-123.49-460.49-312.95-249.68-1,084.16-454.45-1,625.030.9119-18.950.0116--31.9935.55-12.92--18.26--
ScandiDos AB61.35m-9.67m99.77m26.00--2.28--1.63-0.2092-0.20921.270.7660.81841.316.88---12.90-12.60-23.54-21.9350.3951.58-15.76-15.370.9476-6.360.00---1.824.36-60.62---19.29--
BBS-Bioactive Bone Substitutes Oyj0.00-39.56m101.60m----1.16-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
Observe Medical ASA-97.07bn-97.07bn105.31m5.00--0.6921----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
Iconovo AB6.10m-39.03m106.33m29.00--0.8659--17.44-3.01-3.010.45267.710.0434--1.04210,251.40-27.76-25.43-31.28-28.24323.68134.57-640.15-215.16----0.0669---58.65-9.884.71--34.70--
Redsense Medical AB (publ)23.77m-3.98m108.54m5.00--3.38--4.57-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
Episurf Medical AB12.10m-84.60m111.45m26.00--0.9476--9.21-0.2429-0.24290.03470.18070.0839--6.21432,142.80-58.81-47.46-67.73-52.01-----700.83-1,019.296.11--0.0321--53.6219.78-22.64---0.4158--
Luxbright AB4.20m-22.23m114.94m10.00--3.86--27.35-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Glycorex Transplantation AB (publ)31.03m-27.83m118.94m15.00--3.25--3.83-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
BibbInstruments AB0.00-11.84m124.41m4.00--3.60-----0.4417-0.44170.001.180.00-------31.46-39.57-33.52-42.71--59.36---8,032.404.34--0.00------2.72---1.94--
Phase Holographic Imaging PHI AB9.12m-21.81m155.06m17.00------17.00-0.8819-0.88190.3689-0.02730.23730.65981.18---56.73-62.04-88.25-79.6471.0663.16-239.04-328.500.1916-5.611.04--6.1617.9612.98--21.19--
Vo2 Cap Holding AB (publ)344.05m-3.18m162.68m95.00--0.70943.670.4729-0.0594-0.05946.494.030.7088--7.973,340,253.00-0.6554-0.2564-0.8674-0.383935.8423.36-0.9246-0.2409--0.32010.1362---26.0985.65-57.92---17.96--
Data as of Sep 20 2024. Currency figures normalised to BibbInstruments AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Aktia Bank Plc (Investment Management)as of 30 Aug 20241.41m0.00%
Schroder Investment Management Ltd.as of 31 Dec 2023751.47k0.00%
AIFM Capital ABas of 31 Dec 2023677.76k0.00%
Data from 31 Dec 2023 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.